Search

Displaying results 6131 - 6140 of 10000 in total
  1. Drug

    C31G

    go.drugbank.com/drugs/DB05398
    Investigational

    in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV). … C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment

  2. Drug

    QS-21

    go.drugbank.com/drugs/DB05400
    Investigational

    As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics. … QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment

  3. Drug

    CEP-1347

    go.drugbank.com/drugs/DB05403
    Investigational

    CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons

    Categories: Heterocyclic Compounds, 2-Ring, Heterocyclic Compounds, 3-Ring
  4. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

    Categories: GABA-A Receptor Agonists
  5. Drug

    XTL-001

    go.drugbank.com/drugs/DB05405
    Investigational

    investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B

    International brands: HepeX-B
  6. Drug

    GTI-2501

    go.drugbank.com/drugs/DB05406
    Experimental

    GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. … The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.

  7. Drug

    Emricasan

    go.drugbank.com/drugs/DB05408
    Investigational

    It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.

  8. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG). … According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  9. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

  10. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

    Categories: Heterocyclic Compounds, 1-Ring